NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX) from its SEC filings: 2025 revenue $2.9 billion (+21% vs the year before), net margin 17%, free cash flow $748.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $2.9 billion |
| Revenue growth | +21% |
| Net income | $478.6 million |
| Net margin | 16.7% |
| Free cash flow | $748.7 million |
| Diluted EPS | $4.67 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +40% |
| Cash | $332.4 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.